[Journal logo]

Volume 64 
Part 6 
Page o1058  
June 2008  

Received 30 April 2008
Accepted 7 May 2008
Online 10 May 2008

[lh2624sup1]
[3d view]

[Cited in]
[Download citation]
Key indicators
Single-crystal X-ray study
T = 100 K
Mean [sigma](C-C) = 0.002 Å
R = 0.060
wR = 0.206
Data-to-parameter ratio = 15.1
Details
Open access

N-(2-Methoxyethyl)phthalimide

Yoke Leng Sim,a Azhar Ariffina and Seik Weng Nga*

aDepartment of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia
Correspondence e-mail: seikweng@um.edu.my

The title molecule, C11H11NO3, lies on a crystallographic mirror plane which bisects the plane of the phthalimide unit and contains the C and O atoms of the 2-methoxyethyl group.

Related literature

For medicinal properties of the title compound, see: Chapman et al. (1989[Chapman, J. M., Sowell, J. W., Abdalla, G., Hall, I. H. & Wong, O. T. (1989). J. Pharm. Sci. 78, 903-909.]); Hall et al. (1994[Hall, I. H., Chapman, J. M. & Wong, O. T. (1994). Anti-Cancer Drugs, 5, 75-82.]). For a kinetic study of the reaction that yields the title compound, see: Khan (1994[Khan, M. N. (1994). Indian J. Chem. B33, 646-650.]).

[Scheme 1]

Experimental

Crystal data

  • C11H11NO3

  • Mr = 205.21

  • Orthorhombic, P n m a

  • a = 7.0514 (2) Å

  • b = 9.3852 (2) Å

  • c = 14.6024 (4) Å

  • V = 966.37 (4) Å3

  • Z = 4

  • Mo K[alpha] radiation

  • [mu] = 0.10 mm-1

  • T = 100 (2) K

  • 0.30 × 0.20 × 0.10 mm
Data collection

  • Bruker SMART APEX diffractometer

  • Absorption correction: none

  • 7349 measured reflections

  • 1164 independent reflections

  • 986 reflections with I > 2[sigma](I)

  • Rint = 0.039
Refinement

  • R[F2 > 2[sigma](F2)] = 0.059

  • wR(F2) = 0.206

  • S = 1.11

  • 1164 reflections

  • 77 parameters

  • H-atom parameters constrained

  • [Delta][rho]max = 0.50 e Å-3

  • [Delta][rho]min = -0.50 e Å-3

Data collection: APEX2 (Bruker, 2007[Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.]); cell refinement: SAINT (Bruker, 2007[Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.]); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); molecular graphics: X-SEED (Barbour, 2001[Barbour, L. J. (2001). J. Supramol. Chem. 1, 189-191.]); software used to prepare material for publication: publCIF (Westrip, 2008[Westrip, S. P. (2008). publCIF. In preparation.]).

Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: LH2624 ).

Acknowledgements

We thank the SAGA grant (06-02-03-0147) for supporting this study, and the University of Malaya for the purchase of the diffractometer.

References

Barbour, L. J. (2001). J. Supramol. Chem. 1, 189-191.  [CrossRef] [ChemPort]
Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
Chapman, J. M., Sowell, J. W., Abdalla, G., Hall, I. H. & Wong, O. T. (1989). J. Pharm. Sci. 78, 903-909.  [CrossRef] [ChemPort] [PubMed]
Hall, I. H., Chapman, J. M. & Wong, O. T. (1994). Anti-Cancer Drugs, 5, 75-82.  [ChemPort] [PubMed]
Khan, M. N. (1994). Indian J. Chem. B33, 646-650.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [details]
Westrip, S. P. (2008). publCIF. In preparation.

Acta Cryst (2008). E64, o1058  [ doi:10.1107/S1600536808013548 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.